Solid Biosciences (SLDB) Other Accumulated Expenses (2017 - 2024)
Solid Biosciences (SLDB) reported Other Accumulated Expenses of $92000.0 for Q1 2024, up 67.27% on a YoY basis from $55000.0 in Q2 2023, and up 283.33% sequentially from $24000.0 in Q4 2023.
Solid Biosciences (SLDB) Other Accumulated Expenses (2017 - 2024) Analysis & Trends
Solid Biosciences (SLDB) has 7 years of Other Accumulated Expenses data on file, last reported at $92000.0 in Q1 2024.
- For the quarter ending Q1 2024, Other Accumulated Expenses rose 67.27% year-over-year to $92000.0; the trailing twelve-month figure through Mar 2024 stood at $92000.0 (up 67.27% YoY), and the FY2023 full-year result was $24000.0, up 71.43% from the prior year.
- Other Accumulated Expenses improved to $92000.0 in Q1 2024, from $24000.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $162000.0 in Q3 2023 to a low of $14000.0 in Q4 2022.
- A 4-year average of $74250.0 and a median of $67000.0 in 2021 frame the typical range for Other Accumulated Expenses.
- Peak annual rise in Other Accumulated Expenses reached 408.7% in 2023, while the deepest fall reached 63.33% in 2023.
- Tracing SLDB's Other Accumulated Expenses over 4 years: stood at $35000.0 in 2021, then tumbled by 60.0% to $14000.0 in 2022, then soared by 71.43% to $24000.0 in 2023, then soared by 283.33% to $92000.0 in 2024.
- Business Quant data shows SLDB's Other Accumulated Expenses at $92000.0 in Q1 2024, $24000.0 in Q4 2023, and $162000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Solid Biosciences | 529.40 Mn | 529.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 92,000.00 |
| Dec 31, 2023 | 24,000.00 |
| Sep 30, 2023 | 162,000.00 |
| Jun 30, 2023 | 117,000.00 |
| Mar 31, 2023 | 55,000.00 |
| Dec 31, 2022 | 14,000.00 |
| Sep 30, 2022 | 85,000.00 |
| Jun 30, 2022 | 23,000.00 |
| Mar 31, 2022 | 150,000.00 |
| Dec 31, 2021 | 35,000.00 |
| Sep 30, 2021 | 73,000.00 |
| Jun 30, 2021 | 61,000.00 |
| Dec 31, 2019 | 52,000.00 |
| Sep 30, 2019 | 221,000.00 |
| Jun 30, 2019 | 278,000.00 |
| Mar 31, 2019 | 355,000.00 |
| Dec 31, 2018 | 382,000.00 |
| Dec 31, 2017 | 233,000.00 |